SMMT Earnings Date: Nov 2, 2026 (Estimated) — Summit Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SMMT's next earnings date?
Summit Therapeutics Inc. (SMMT) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.28 on revenue of $71,429.
How did SMMT do in its last earnings report?
In its most recent report on Jul 23, 2026 (Q2 2026), Summit Therapeutics Inc. posted EPS of -$0.19 versus the -$0.22 estimate, a beat of 13.6%. Revenue was $0 against a $88,500 estimate. The stock's 1-day post-earnings move was -8.8%.
How much does SMMT stock move after earnings?
SMMT beat EPS estimates in 4 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 10.8% (up or down) in the day after earnings.
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
🤖 AI Earnings Analysis
SMMT’s key catalyst is ivonescimab’s reported overall-survival superiority in first-line biliary cancer, but its negative 13.8 P/E underscores ongoing losses and clinical risk.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-23 | Q2 2026 | -0.22 | -0.19 | +13.64% | $0 | ✅ Beat | -8.81% | -10.28% | -12.15% |
| 2026-04-30 | Q1 2026 | -0.23 | -0.15 | +34.78% | $0 | ✅ Beat | -24.91% | -20.08% | -26.79% |
| 2026-02-23 | Q4 2025 | -0.10 | -0.14 | -40.00% | $0 | ❌ Miss | +0.19% | +0.62% | -3.42% |
| 2025-10-20 | Q3 2025 | -0.08 | -0.13 | -62.50% | $0 | ❌ Miss | -4.55% | -8.15% | -19.25% |
| 2025-08-11 | Q2 2025 | -0.08 | -0.12 | -50.00% | $0 | ❌ Miss | -9.08% | -6.94% | -37.68% |
| 2025-02-24 | Q4 2024 | -0.08 | -0.07 | +12.50% | $0 | ✅ Beat | -14.83% | -6.46% | -6.46% |
| 2024-08-06 | Q2 2024 | -0.06 | -0.05 | +16.67% | $0 | ✅ Beat | -4.74% | +9.64% | +19.82% |
| 2024-05-01 | Q1 2024 | — | -0.06 | — | $0 | — | +19.59% | +35.11% | +177.86% |
Showing last 8 quarters.